Elefante Mark B Novartis Ag Call Options Transaction History
Elefante Mark B
- $126 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding NVS
# of Institutions
1,522Shares Held
142MCall Options Held
1.53MPut Options Held
1.79M-
Dodge & Cox San Francisco, CA11.8MShares$1.28 Billion0.81% of portfolio
-
Primecap Management CO Pasadena, CA10.4MShares$1.13 Billion0.98% of portfolio
-
Dimensional Fund Advisors LP Austin, TX8.61MShares$933 Million0.25% of portfolio
-
Morgan Stanley New York, NY7.06MShares$765 Million0.06% of portfolio
-
Ken Fisher Fisher Asset Management, LLC | Camas, Wa6.76MShares$734 Million0.33% of portfolio
About NOVARTIS AG
- Ticker NVS
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,151,000,064
- Market Cap $233B
- Description
- Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...